NCT02808260 Predicting Development of SCAF in Device Patients
| NCT ID | NCT02808260 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ottawa Heart Institute Research Corporation |
| Condition | Atrial Fibrillation |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2034-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2022-09-01 with a primary completion date of 2034-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Atrial fibrillation (AF) often starts with short episodes of rapid irregular heartbeats that are only detected by implanted pacemakers or defibrillators. Usually people don't know that they have these episodes. Over time, these episodes can happen more often and last for longer periods. In some people, the heart eventually remains permanently in a fast irregular rhythm, known as atrial fibrillation. This condition can lead to strokes and blood clots. If physicians could detect atrial fibrillation at a very early stage they could treat people early and possibly prevent the condition from becoming permanent. People with implanted devices allow a unique opportunity to constantly monitor the heart rhythm so investigators can detect any irregularities immediately. Investigators don't know which people are at risk of developing short episodes of fast irregular heartbeats that can lead to atrial fibrillation. The purpose of this study is to find out if there are proteins or chemical changes in the blood that can predict the risk of developing atrial fibrillation. These chemical changes, also known as biomarkers, may also be able to give investigators other clues about atrial fibrillation.
Eligibility Criteria
Inclusion Criteria: • Dual chamber permanent pacemaker or defibrillator implanted within previous 10 years Exclusion Criteria: * Clinical atrial fibrillation documented by surface ECG (12 lead ECG, Telemetry, Holter) * Participants considered by the investigator to be unsuitable for the study for the following reason: life expectancy less than 2 years due to concomitant disease * Participants who are pregnant or breast-feeding * Congenital heart disease * Inherited arrhythmia syndrome, i.e. Brugada, long QT interval
Contact & Investigator
Pablo Nery, MD
PRINCIPAL INVESTIGATOR
Ottawa Heart Institute Research Corporation
Frequently Asked Questions
Who can join the NCT02808260 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02808260 currently recruiting?
Yes, NCT02808260 is actively recruiting participants. Contact the research team at tknight@ottawaheart.ca for enrollment information.
Where is the NCT02808260 trial being conducted?
This trial is being conducted at Ottawa, Canada.
Who is sponsoring the NCT02808260 clinical trial?
NCT02808260 is sponsored by Ottawa Heart Institute Research Corporation. The principal investigator is Pablo Nery, MD at Ottawa Heart Institute Research Corporation. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.